SEC Form 4 · accession 0000899243-19-004673
T2 Biosystems, Inc. · TTOO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alec Barclay
Officer — SVP, Operations
Period of report
Feb 21, 2019
Accepted (ET)
Feb 25, 2019 · 3:37 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492674
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $3.72 | Feb 21, 2019 | A | 60,000 | A | — | Feb 21, 2029 | Common Stock | 60,000 | 60,000 | D |
| Restricted Stock UnitsF2,F3 | — | Feb 21, 2019 | A | 30,000 | A | — | — | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1The stock option vests in 48 equal monthly installments commencing February 21, 2019.
- F2Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F3The restricted stock units vest in three equal annual installments commencing February 21, 2020.